Your browser doesn't support javascript.
Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom.
Török, M Estée; Underwood, Benjamin R; Toshner, Mark; Waddington, Claire; Sidhom, Emad; Sharrocks, Katherine; Bousfield, Rachel; Summers, Charlotte; Saunders, Caroline; McIntyre, Zoe; Morris, Helen; Piper, Jo; Calderon, Gloria; Dennis, Sarah; Assari, Tracy; de Rotrou, Anita Marguerie; Shaw, Ashley; Bradley, John; O'Brien, John; Rintoul, Robert C; Smith, Ian; Bullmore, Ed; Chatterjee, Krishna.
  • Török ME; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Underwood BR; Departments of Infectious Diseases & Microbiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Toshner M; Public Health England, Clinical Microbiology and Public Health Laboratory, Cambridge, UK.
  • Waddington C; Windsor Research Unit, Fulbourn Hospital, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
  • Sidhom E; Gnodde Goldman Sachs Translational Neuroscience Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Sharrocks K; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Bousfield R; Department of Respiratory Medicine, Royal Papworth Hospital, Cambridge, UK.
  • Summers C; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Saunders C; Departments of Infectious Diseases & Microbiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • McIntyre Z; Windsor Research Unit, Fulbourn Hospital, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
  • Morris H; Gnodde Goldman Sachs Translational Neuroscience Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Piper J; Departments of Infectious Diseases & Microbiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Calderon G; Public Health England, Clinical Microbiology and Public Health Laboratory, Cambridge, UK.
  • Dennis S; Departments of Infectious Diseases & Microbiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Assari T; Public Health England, Clinical Microbiology and Public Health Laboratory, Cambridge, UK.
  • de Rotrou AM; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Shaw A; John V Farman Intensive Care Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Bradley J; NIHR Cambridge Clinical Research Facility, Cambridge Clinical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • O'Brien J; Office for Translational Research, University of Cambridge, Cambridge, UK.
  • Rintoul RC; NIHR Cambridge Clinical Research Facility, Cambridge Clinical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Smith I; NIHR Cambridge Clinical Research Facility, Cambridge Clinical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Bullmore E; Windsor Research Unit, Fulbourn Hospital, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
  • Chatterjee K; Department of Respiratory Medicine, Royal Papworth Hospital, Cambridge, UK.
Clin Trials ; 18(5): 615-621, 2021 10.
Article in English | MEDLINE | ID: covidwho-1280563
ABSTRACT
The COVID-19 pandemic has resulted in unprecedented challenges for healthcare systems worldwide. It has also stimulated research in a wide range of areas including rapid diagnostics, novel therapeutics, use of technology to track patients and vaccine development. Here, we describe our experience of rapidly setting up and delivering a novel COVID-19 vaccine trial, using clinical and research staff and facilities in three National Health Service Trusts in Cambridgeshire, United Kingdom. We encountered and overcame a number of challenges including differences in organisational structures, research facilities available, staff experience and skills, information technology and communications infrastructure, and research training and assessment procedures. We overcame these by setting up a project team that included key members from all three organisations that met at least daily by teleconference. This group together worked to identify the best practices and procedures and to harmonise and cascade these to the wider trial team. This enabled us to set up the trial within 25 days and to recruit and vaccinate the participants within a further 23 days. The lessons learned from our experiences could be used to inform the conduct of clinical trials during a future infectious disease pandemic or public health emergency.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Clinical Trials as Topic / Pandemics / COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study / Qualitative research / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: Clin Trials Journal subject: Medicine / Therapeutics Year: 2021 Document Type: Article Affiliation country: 17407745211024764

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Clinical Trials as Topic / Pandemics / COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study / Qualitative research / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: Clin Trials Journal subject: Medicine / Therapeutics Year: 2021 Document Type: Article Affiliation country: 17407745211024764